コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 an increase in the probability of surviving Ebola virus infection.
2 s what is known about the natural history of Ebola virus infection.
3 nterventions for controlling the outbreak of Ebola virus infection.
4 e the cellular immune responses during acute Ebola virus infection.
5 erspectives for treatment strategies against Ebola virus infection.
6 ll travellers at highest risk of exposure to Ebola virus infection.
7 ness and multiple organ failure secondary to Ebola virus infection.
8 further improved protective efficacy against Ebola virus infection.
9 tic efficacy in a non-human primate model of Ebola virus infection.
10 es affect the efficacy of protection against Ebola virus infection.
11 tinct disease phenotypes after mouse-adapted Ebola virus infection.
12 asures for post-exposure prophylaxis against Ebola virus infection.
13 important role in the immunopathogenesis of Ebola virus infection.
14 development of antiviral compounds to combat Ebola virus infection.
15 mediated immune responses in protection from Ebola virus infection.
16 n the clearance and protection against fatal Ebola virus infection.
17 t the innate immune system, for treatment of Ebola virus infection.
18 are potentially critical for survival after Ebola virus infection.
19 d a decisive role for NK cells during lethal Ebola virus infection.
20 critical to protection against subcutaneous Ebola virus infection.
21 ting that this receptor is not essential for Ebola virus infection.
22 promising candidate for immunoprophylaxis of Ebola virus infection.
23 y to the Ebola virus glycoprotein, enhancing Ebola virus infection.
24 ected upto 100% of naive mice against lethal Ebola virus infection.
25 polyclonal immune serum in a mouse model of Ebola virus infection.
26 and would play a role in the pathogenesis of Ebola virus infection.
27 d to cure animals from this otherwise lethal Ebola virus infection.
28 and translate it into treatment options for Ebola virus infection.
29 e design and as a prophylactic agent against Ebola virus infection.
30 ed intracellular cholesterol trafficking and Ebola virus infection.
31 ca experienced an unanticipated explosion of Ebola virus infections.
32 in 28 646 suspected, probable, and confirmed Ebola virus infections.
33 velopment of circulatory shock seen in fatal Ebola virus infections.
34 t immune responses during the acute phase of Ebola virus infection, a finding that would not have bee
36 e demonstration that CTLs can prevent lethal Ebola virus infection affects vaccine development in tha
38 Therefore, TPC proteins play a key role in Ebola virus infection and may be effective targets for a
39 e with VLPs had no protective effect against Ebola virus infection and NK cells treated with VLPs pro
40 T cells are required for natural immunity to Ebola virus infection and that CD4-dependent antibody re
41 tible models to BDBV infection as well as to Ebola virus infection and that no virus adaptation is re
42 ostic test is needed to confirm outbreaks of Ebola virus infection and to distinguish it from other d
43 ing vaccine candidate for protection against Ebola virus infections and a much needed tool to examine
44 verage human levels survived otherwise fatal Ebola virus infections and became immune to virus rechal
45 al growth, provide protection against lethal Ebola virus infection, and may not require participation
47 tenuates lethality in experimental models of Ebola virus infection but - similar to findings in bacte
49 e chain reaction (RT-PCR)-based diagnosis of Ebola virus infection currently requires a blood sample
50 eful for the analysis of immune responses to Ebola virus infection, development of neutralizing antib
52 of GP was thought to be an essential step in Ebola virus infection, generation of a viable mutant Ebo
53 virus GP(1,2), as well as Marburg virus and Ebola virus infection in a dose-dependent manner and at
54 recorded zoonotic transmission to humans and Ebola virus infection in bats and primates (1976-2014).
55 et of illness and laboratory confirmation of Ebola virus infection in Europe or the United States, an
57 were effective for detecting and containing Ebola virus infection in newly imported nonhuman primate
62 43-year-old medical doctor who contracted an Ebola virus infection in Sierra Leone on Nov 16, 2014 (d
63 , including those with proposed relevance to Ebola virus infection in vivo, such as endothelial cells
67 March 2015, the largest recorded outbreak of Ebola virus infection is ongoing, with almost 25 000 cas
70 tissue damage in fatal EVD, and suggest that Ebola virus infection may induce aberrant neutrophils wh
71 dy-positive HHCs suggests that mild cases of Ebola virus infection occurred and that the full extent
75 or amplify proinflammatory signaling during Ebola virus infection, potentially contributing to the d
76 us protein (VP)40, administered 1-3 d before Ebola virus infection rapidly induced protective immunit
77 expected number of internationally exported Ebola virus infections, the potential effect of air trav
80 A passive immunization strategy for treating Ebola virus infections was evaluated using BALB/ c mice,
81 to be increased in patients with fatal Zaire Ebola virus infection, were not increased in any of the
82 NK cells treated with VLPs protected against Ebola virus infection when adoptively transferred to nai
83 from all patients with laboratory-confirmed Ebola virus infection who received care in U.S. and Euro
84 est Africa experienced the first epidemic of Ebola virus infection, with by far the greatest number o
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。